IMU-131 is under clinical development by Imugene and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMU-131’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMU-131 (Her-Vaxx) is under development for the treatment of adenocarcinoma of the gastroesophageal junction, breast cancer, ovarian cancer, non small cell lung cancer, HER-2 positive advanced gastric cancer, pancreatic cancer and bladder cancer. It is administered intramuscularly. Her-Vaxx is an virosome-based cancer vaccine using synthetic epidermal growth factor (EGF) receptor 2 (HER2; ErbB2; neu) antigens. The vaccine candidate is made up of two components, the peptide antigen P4, P6 and P7 and the vaccine delivery adjuvant CRM197. It is a multi-B cell peptide vaccine against Her-2/neu (including CRM carrier and adjuvant Montanide).
Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology immune. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company’s pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
For a complete picture of IMU-131’s drug-specific PTSR and LoA scores, buy the report here.